CRISPR Therapeutics AG (NASDAQ:CRSP) went down by -3.92% from its latest closing price compared to the recent 1-year high of $220.20. The company’s stock price has collected 1.23% of gains in the last five trading sessions. Press Release reported on 11/23/21 that CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ :CRSP) Right Now?
CRISPR Therapeutics AG (NASDAQ:CRSP) scored a price-to-earnings ratio above its average ratio, recording 14.67 x from its present earnings ratio. Plus, the 36-month beta value for CRSP is at 2.07. Opinions of the stock are interesting as 16 analysts out of 24 who provided ratings for CRISPR Therapeutics AG declared the stock was a “buy,” while 0 rated the stock as “overweight,” 7 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $150.15, which is $79.25 above the current price. CRSP currently public float of 72.25M and currently shorts hold a 11.14% ratio of that float. Today, the average trading volume of CRSP was 1.64M shares.
CRSP’s Market Performance
CRSP stocks went up by 1.23% for the week, with a monthly drop of -4.30% and a quarterly performance of -27.81%, while its annual performance rate touched -63.96%. The volatility ratio for the week stands at 6.84% while the volatility levels for the past 30 days are set at 7.00% for CRISPR Therapeutics AG. The simple moving average for the period of the last 20 days is -8.12% for CRSP stocks with a simple moving average of -36.57% for the last 200 days.
Analysts’ Opinion of CRSP
SVB Leerink, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $126. The rating they have provided for CRSP stocks is “Outperform” according to the report published on October 19th, 2021.
Citigroup gave a rating of “Neutral” to CRSP, setting the target price at $132 in the report published on June 14th of the previous year.
CRSP Trading at -13.03% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.27% of loss for the given period.
Volatility was left at 7.00%, however, over the last 30 days, the volatility rate increased by 6.84%, as shares sank -6.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.82% lower at present.
During the last 5 trading sessions, CRSP rose by +1.23%, which changed the moving average for the period of 200-days by -39.36% in comparison to the 20-day moving average, which settled at $75.79. In addition, CRISPR Therapeutics AG saw -7.81% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CRSP starting from TOMSICEK MICHAEL JOHN, who sale 25,000 shares at the price of $138.52 back on Aug 06. After this action, TOMSICEK MICHAEL JOHN now owns 1,891 shares of CRISPR Therapeutics AG, valued at $3,462,926 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 28,500 shares at $128.98 during a trade that took place back on Aug 05, which means that Kulkarni Samarth is holding 187,719 shares at $3,675,939 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -49295.55 for the present operating margin
The net margin for CRISPR Therapeutics AG stands at -48520.86. The total capital return value is set at -26.08, while invested capital returns managed to touch -25.86. Equity return is now at value 19.20, with 17.30 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 3.69 points at debt to equity in total, while total debt to capital is 3.56. Total debt to assets is 3.36, with long-term debt to equity ratio resting at 3.01. Finally, the long-term debt to capital ratio is 2.90.
When we switch over and look at the enterprise to sales, we see a ratio of 4.36, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 0.10 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.21.